Literature DB >> 11239457

A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

D M Keller1, X Zeng, Y Wang, Q H Zhang, M Kapoor, H Shu, R Goodman, G Lozano, Y Zhao, H Lu.   

Abstract

Phosphorylation of the human p53 protein at Ser-392 has been shown to be responsive to UV but not gamma irradiation. Here we describe identification and purification of a mammalian UV-activated protein kinase complex that phosphorylates Ser-392 of p53 in vitro. This kinase complex contains casein kinase 2 (CK2) and the chromatin transcriptional elongation factor FACT (a heterodimer of hSpt16 and SSRP1). In vitro studies show that FACT alters the specificity of CK2 in the complex such that it selectively phosphorylates p53 over other substrates including casein. In addition, phosphorylation by the kinase complex enhances p53 activity. These results thus provide a potential mechanism for p53 activation by UV irradiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239457     DOI: 10.1016/s1097-2765(01)00176-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  109 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

Review 2.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

3.  The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Authors:  David Dornan; Harumi Shimizu; Lindsay Burch; Amanda J Smith; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

4.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Authors:  Alexander V Gasparian; Catherine A Burkhart; Andrei A Purmal; Leonid Brodsky; Mahadeb Pal; Madhi Saranadasa; Dmitry A Bosykh; Mairead Commane; Olga A Guryanova; Srabani Pal; Alfiya Safina; Sergey Sviridov; Igor E Koman; Jean Veith; Anton A Komar; Andrei V Gudkov; Katerina V Gurova
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

6.  Covalent DNA-Protein Cross-Linking by Phosphoramide Mustard and Nornitrogen Mustard in Human Cells.

Authors:  Arnold Groehler; Peter W Villalta; Colin Campbell; Natalia Tretyakova
Journal:  Chem Res Toxicol       Date:  2016-01-20       Impact factor: 3.739

7.  CK2 phosphorylation of eukaryotic translation initiation factor 5 potentiates cell cycle progression.

Authors:  Miwako Kato Homma; Ikuo Wada; Toshiyuki Suzuki; Junko Yamaki; Edwin G Krebs; Yoshimi Homma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-14       Impact factor: 11.205

8.  Regulation of NuA4 histone acetyltransferase activity in transcription and DNA repair by phosphorylation of histone H4.

Authors:  Rhea T Utley; Nicolas Lacoste; Olivier Jobin-Robitaille; Stéphane Allard; Jacques Côté
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Ability of CK2beta to selectively regulate cellular protein kinases.

Authors:  Birgitte B Olsen; Barbara Guerra
Journal:  Mol Cell Biochem       Date:  2008-06-17       Impact factor: 3.396

10.  CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Authors:  P P Scaglioni; T M Yung; S Choi; S C Choi; C Baldini; G Konstantinidou; P P Pandolfi
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.